MK-0653H
Total Payments
$191,264
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $191,264 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $191,264 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A study to determine the bioeqiuvalence of MK-0653H 10,20 mg compared to Brazilian reference products in healthy adults | Merck Sharp & Dohme Corporation | $183,530 | 0 |
| A study to determine the bioeqiuvalence of MK-0653H 10,20 mg compared to South African reference products in healthy adults | Merck Sharp & Dohme Corporation | $7,734 | 0 |
Top Doctors Receiving Payments for MK-0653H
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | — | $191,264 | 4 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $191,264
Product Information
- Type Drug
- Total Payments $191,264
- Total Doctors 0
- Transactions 4
About MK-0653H
MK-0653H is a drug associated with $191,264 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $191,264 was paid across 4 transactions to 0 doctors.
The most common payment nature for MK-0653H is "Unspecified" ($191,264, 100.0% of total).
MK-0653H is associated with 2 research studies, including "A study to determine the bioeqiuvalence of MK-0653H 10,20 mg compared to Brazilian reference products in healthy adults" ($183,530).